170 related articles for article (PubMed ID: 24159011)
1. Evaluation of tumor-induced osteomalacia with 111In-pentetreotide scintigraphy.
Palot Manzil FF; Bhambhvani PG; O'Malley JP
J Nucl Med Technol; 2013 Dec; 41(4):299-301. PubMed ID: 24159011
[TBL] [Abstract][Full Text] [Related]
2. Localisation of mesenchymal tumours by somatostatin receptor imaging.
Jan de Beur SM; Streeten EA; Civelek AC; McCarthy EF; Uribe L; Marx SJ; Onobrakpeya O; Raisz LG; Watts NB; Sharon M; Levine MA
Lancet; 2002 Mar; 359(9308):761-3. PubMed ID: 11888589
[TBL] [Abstract][Full Text] [Related]
3. Tumor-induced osteomalacia: successful treatment by radio-guided tumor surgery.
Harbeck B; Schöcklmann H; Seekamp A; Czech N; Mönig H
J Clin Rheumatol; 2009 Feb; 15(1):31-4. PubMed ID: 19125132
[TBL] [Abstract][Full Text] [Related]
4. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia.
Nguyen BD; Wang EA
Clin Nucl Med; 1999 Feb; 24(2):130-1. PubMed ID: 9988077
[No Abstract] [Full Text] [Related]
5. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia.
Duet M; Kerkeni S; Sfar R; Bazille C; Lioté F; Orcel P
Clin Nucl Med; 2008 Nov; 33(11):752-6. PubMed ID: 18936605
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
Seijas R; Ares O; Sierra J; Pérez-Dominguez M
Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
[TBL] [Abstract][Full Text] [Related]
7. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.
Breer S; Brunkhorst T; Beil FT; Peldschus K; Heiland M; Klutmann S; Barvencik F; Zustin J; Gratz KF; Amling M
Bone; 2014 Jul; 64():222-7. PubMed ID: 24769333
[TBL] [Abstract][Full Text] [Related]
8. A case of oncogenic osteomalacia detected by 111In-pentetreotide total body scan.
Casari S; Rossi V; Varenna M; Gasparini M; Parafioriti A; Failoni S; Sinigaglia L
Clin Exp Rheumatol; 2003; 21(4):493-6. PubMed ID: 12942704
[TBL] [Abstract][Full Text] [Related]
9. [Oncogenic osteomalacia: localization of underlying peripheral tumor with 99mTc-sestamibi scintigraphy].
Biagini GL; Coutinho PR; Jonasson TH; Ueda CE; Gama RR
Arq Bras Endocrinol Metabol; 2008 Dec; 52(9):1505-9. PubMed ID: 19197461
[TBL] [Abstract][Full Text] [Related]
10. Osteomalacia-inducing renal clear cell carcinoma uncovered by 99mTc-Hydrazinonicotinyl-Tyr3-octreotide (99mTc-HYNIC-TOC) scintigraphy.
Jin X; Jing H; Li F; Zhuang H
Clin Nucl Med; 2013 Nov; 38(11):922-4. PubMed ID: 24089059
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy.
Rhee Y; Lee JD; Shin KH; Lee HC; Huh KB; Lim SK
Clin Endocrinol (Oxf); 2001 Apr; 54(4):551-4. PubMed ID: 11318793
[TBL] [Abstract][Full Text] [Related]
12. Concordance between whole-body scintigraphy 111In-octreotide and 99mTc-sestamibi uptake in the detection of four tumor-induced osteomalacia cases.
Ferraz MP; Watanabe T; Sado HN; Ono CR; Buchpiguel CA; Correa PH; Martin RM
J Clin Endocrinol Metab; 2014 Mar; 99(3):699-700. PubMed ID: 24423352
[No Abstract] [Full Text] [Related]
13. En bloc resection for treatment of tumor-induced osteomalacia: a case presentation and a systematic review.
Meng T; Zhou W; Li B; Yin H; Li Z; Zhou L; Kong J; Yan W; Yang X; Liu T; Song D; Xiao J
World J Surg Oncol; 2015 May; 13():176. PubMed ID: 25951872
[TBL] [Abstract][Full Text] [Related]
14. Tumor-induced hypophosphatemic osteomalacia associated with tertiary hyperparathyroidism: a case report.
Tartaglia F; Minisola S; Sgueglia M; Blasi S; Brunelli D; Degli Effetti E; Maturo A; Cola A; Custureri F; Campana FP
G Chir; 2006; 27(1-2):9-13. PubMed ID: 16608626
[TBL] [Abstract][Full Text] [Related]
15. 111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors.
Nauck C; Ivancević V; Emrich D; Creutzfeldt W
Z Gastroenterol; 1994 Jun; 32(6):323-7. PubMed ID: 7975760
[TBL] [Abstract][Full Text] [Related]
16. [Receptor scintigraphy using 111In-pentetreotide in endocrine gastroenteropancreatic tumors].
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Benning R; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Nuklearmedizin; 1993 Dec; 32(6):299-305. PubMed ID: 7905200
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography.
Hesse E; Moessinger E; Rosenthal H; Laenger F; Brabant G; Petrich T; Gratz KF; Bastian L
J Bone Miner Res; 2007 Jan; 22(1):158-62. PubMed ID: 17014386
[TBL] [Abstract][Full Text] [Related]
18. Indium-111-pentetreotide scintigraphy in children with neuroblast-derived tumors.
Manil L; Edeline V; Lumbroso J; Lequen H; Zucker JM
J Nucl Med; 1996 Jun; 37(6):893-6. PubMed ID: 8683306
[TBL] [Abstract][Full Text] [Related]
19. Bone scintigraphy in a case of oncogenous osteomalacia.
Ohta H; Nakaishi S; Oki S; Simizu M; Watanabe H; Fujikawa S; Nakade M; Watanabe H; Kohno K; Shintaku M
Clin Nucl Med; 1998 Jul; 23(7):467-9. PubMed ID: 9676956
[No Abstract] [Full Text] [Related]
20. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
